The invention herein, has as objective demonstrating the use of dapsone as the first efficient in the treatment against the disabling consequences associated with brain stroke in these patients. Dapsone was evaluated as a nouroprotector, in the model of brain stroke produced by the occlusion of the middle cerebral artery in rats and in patients suffering from an acute brain stroke by thrombo-embolism. In both studies, dapsone shown a reduction of 70 and 90% of the disabling consequences after ischemic stroke.